Enclomiphene: Contraindications and Drug Interactions
Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM) long used in fertility medicine. It has been studied as a way to raise testosterone in men with secondary hypogonadism while preserving sperm production. Because it acts on the hormonal axis and blood clotting pathways, knowing who should avoid it matters. Our editorial team summarizes the contraindications and interactions.
What enclomiphene is and its status in the US
Clomiphene citrate, approved by the FDA in 1967 for ovulation induction in women, is a mixture of two isomers: enclomiphene (trans) and zuclomiphene (cis). The two behave differently. Enclomiphene acts mainly as an estrogen receptor antagonist and is cleared relatively quickly, whereas zuclomiphene has weaker antiestrogenic activity and lingers in the body for weeks.
That difference led researchers to develop enclomiphene on its own for men. Phase 3 trials reported that it raised serum testosterone while maintaining sperm counts, unlike exogenous testosterone, which suppresses them.
Despite this research, the FDA has not approved enclomiphene as a drug in the United States. A new drug application was not approved, in part over questions about trial design and endpoints. In the US, enclomiphene has been supplied through compounding pharmacies, a practice that has drawn regulatory attention.
Enclomiphene and other SERMs are prohibited at all times in sport under the WADA list, in the category of hormone and metabolic modulators. Athletes subject to testing should be aware of this.
How it works and why that shapes safety
Estradiol normally provides negative feedback to the hypothalamus and pituitary, restraining release of gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). By blocking estrogen receptors in the hypothalamus, enclomiphene removes part of this brake.
The result is increased LH and FSH output. LH stimulates Leydig cells in the testes to produce testosterone, while FSH supports spermatogenesis. This is why enclomiphene can only work in men whose testes are capable of responding — it does not help primary testicular failure.
SERMs are not pure antagonists everywhere. In some tissues they act partly like estrogen. For clomiphene and related drugs this includes effects on the liver's production of clotting factors and on lipids, which is why venous thromboembolism is a recognized concern for the SERM class.
Because testosterone rises, some of it is converted to estradiol. Estrogen levels can therefore also increase, with potential effects on mood, libido, and breast tissue.
Absolute and relative contraindications
Because enclomiphene is not an FDA-approved product, there is no official US label listing its contraindications. Clinicians therefore draw on clomiphene citrate labeling, the SERM class profile, and data from enclomiphene trials. The following conditions are generally considered reasons to avoid or use extreme caution.
- History of venous thromboembolism — deep vein thrombosis, pulmonary embolism, or a known inherited clotting disorder.
- Liver disease or dysfunction — clomiphene labeling lists liver disease as a contraindication.
- Primary hypogonadism — the testes cannot respond to higher LH, so the drug is ineffective.
- Pituitary or other intracranial tumors — these need diagnosis and specialist management first.
- Uncontrolled thyroid or adrenal disorders — also listed for clomiphene.
- Prior visual disturbances with clomiphene or another SERM.
- Hormone-sensitive cancers — such as prostate or male breast cancer, where hormonal manipulation requires oncology input.
Visual symptoms deserve special attention. Clomiphene labeling describes blurred vision, spots, and flashes, which usually resolve after stopping but have rarely persisted. Any visual change is a reason to stop and seek an eye examination.
Elevated hematocrit has also been observed when testosterone rises. Men who already have erythrocytosis, or conditions such as untreated sleep apnea that raise red blood cell counts, may need closer evaluation.
Enclomiphene is intended for men; it is not used in pregnancy and should be kept away from women who may become pregnant.
Drug interactions
Formal interaction studies for enclomiphene are limited, so much of the guidance is based on the pharmacology of clomiphene and on mechanisms. Clomiphene is metabolized partly by liver enzymes CYP2D6 and CYP3A4, so drugs that strongly inhibit or induce these enzymes could change exposure.
| Drug or class | Potential concern |
|---|---|
| Exogenous testosterone or other androgens | Suppresses the axis enclomiphene tries to stimulate; additive hematocrit effects |
| Estrogens and other SERMs (tamoxifen, raloxifene) | Overlapping mechanisms; additive clot risk |
| Aromatase inhibitors | Combined hormonal manipulation needs specialist oversight; may lower estradiol excessively |
| Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine, bupropion) | May alter metabolism of clomiphene isomers |
| Anticoagulants | Clot-risk background; clinical judgment required |
| Thyroid hormone, glucocorticoids | Influence on hormone-binding proteins and lab interpretation |
Combining a SERM with testosterone injections defeats its purpose and adds risks. Similarly, combining multiple hormonal drugs without medical supervision makes it impossible to interpret blood tests or attribute side effects.
Supplements marketed for "testosterone support" can also complicate the picture. Some products have been found to contain undeclared drugs, and herbal ingredients may affect liver enzymes.
Always give your physician and pharmacist a complete list of prescription drugs, over-the-counter medicines, and supplements.
Monitoring and warning signs
In clinical research, men taking enclomiphene were monitored with blood tests for testosterone, LH, FSH, estradiol, hematocrit, and lipids, along with semen analysis when fertility was a goal. Similar monitoring is reasonable in practice.
Commonly reported side effects in trials were mild and included headache, hot flushes, nausea, and dizziness. Some men report mood changes or reduced libido if estradiol rises sharply.
Certain symptoms warrant urgent medical attention: leg pain or swelling, sudden shortness of breath or chest pain, any new visual disturbance, severe headache, or signs of liver problems such as yellowing of the skin or dark urine.
Because enclomiphene products in the US come from compounding rather than an approved manufacturer, quality and consistency can vary. A prescriber familiar with male reproductive endocrinology is the safest route.
Conclusions of the editorial team
Enclomiphene is a promising but unapproved option for raising testosterone in men with secondary hypogonadism who want to preserve fertility.
The key contraindications follow from its class: a history of blood clots, liver disease, visual problems, pituitary disease, and hormone-sensitive cancers.
Interactions are most relevant with other hormonal agents and with drugs that alter liver enzyme activity. Proper diagnosis and monitoring are essential.
You may also find our articles on why testosterone does not always recover after a cycle, hyperprolactinemia diagnosis, and the history of testosterone cypionate useful.
References
- Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677–685.
- Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720–727.
- Earl JA, Kim ED. Enclomiphene citrate: a treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157–165.
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744.
- Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril. 1986;46(3):392–396.
